Market capitalization | $498.20m |
Enterprise Value | $180.01m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 3.21 |
P/S ratio (TTM) P/S ratio | 8.89 |
P/B ratio (TTM) P/B ratio | 1.67 |
Revenue growth (TTM) Revenue growth | 12.04% |
Revenue (TTM) Revenue | $56.04m |
As a Free StocksGuide user, you can view scores for all 6,782 stocks worldwide.
13 Analysts have issued a EyePoint Pharmaceuticals, Inc. forecast:
13 Analysts have issued a EyePoint Pharmaceuticals, Inc. forecast:
Mar '25 |
+/-
%
|
||
Revenue | 56 56 |
12%
12%
|
|
Gross Profit | 52 52 |
15%
15%
|
|
EBITDA | -160 -160 |
82%
82%
|
EBIT (Operating Income) EBIT | -161 -161 |
83%
83%
|
Net Profit | -147 -147 |
86%
86%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
Head office | United States |
CEO | Jay Duker |
Employees | 165 |
Founded | 1987 |
Website | eyepointpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.